RxDoctor Payments Data

Natalka Manastersky, OD

Optometrist · Calumet City, ILNPI 1629206628

Payments from drug & device makers

$2,076in general payments, 2019–2025

Across 57 payments — averaging $36.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$344
  • Dompe US, Inc.$322
  • Biotissue Holdings Inc.$310
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$241
  • Sight Sciences, Inc.$221
  • Tarsus Pharmaceuticals, Inc.$146
  • plus $491 from 12 others

What the payments were for

  • Food & beverage$2,076100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,076 in reported general payments places this provider in the 80th percentile of 2,257 optometrist providers in Illinois.

See all optometrist providers in Illinois

Medicare billing

Part B allowed, 2024
$70,265
Medicare patients
216
Services billed
722

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine90$58,676
XiidraLifitegrast27$21,520
LumiganBimatoprost18$13,536
Cyclosporine41$7,220
Alphagan PBrimonidine Tartrate15$3,821
Azelastine Hcl107$3,729
FlarexFluorometholone Acetate12$1,761
Brimonidine Tartrate15$1,680
Latanoprost77$942
Prednisolone Acetate16$765
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha15$152
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat14$138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$46$76,033123 claims
Bausch & Lomb Americas Inc.Xiidra$58$21,52027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,257 optometrist providers in Illinois.

Other optometrist in Calumet City

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →